Fungal Infections in Neutropenic Hematological Disorders

Similar documents
ECMM Excellence Centers Quality Audit

Message from Dr A K Agarwal Chairman Scientific Committee APICON 2009 & President-Elect, Association of Physicians of India (API)

Invasive Pulmonary Aspergillosis in

Indre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong

HAEMATOLOGY ANTIFUNGAL POLICY

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

Common Fungi. Catherine Diamond MD MPH

Neutropenic Sepsis Guideline

Case Studies in Fungal Infections and Antifungal Therapy

Challenges and controversies of Invasive fungal Infections

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary

PAGL Inclusion Approved at January 2017 PGC

Is pre-emptive therapy a realistic approach?

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

amphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY

ESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel

Fungal Infection Post-Infusion Data

TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY

Antifungals and current treatment guidelines in pediatrics and neonatology

Top 5 papers in clinical mycology

The goal of teaching:

Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?

Aspergillus species. The clinical spectrum of pulmonary aspergillosis

Dr. Arghya Samanta PG-3 Department of Pediatrics

The Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT

Aspergillosis in the critically ill patient

Fungal Infections: Reporting. Marcie Tomblyn, MD, MS Associate Member, Moffitt Cancer Center

Management of fungal infection

Oliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research

Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation

When is failure failure?

Fungal Infection Pre-Infusion Data

Use of Antifungals in the Year 2008

Outline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI

Diagnostik invasiver Pilzinfektionen

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

2046: Fungal Infection Pre-Infusion Data

PROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino

TIMM 2013 Role of non-culture biomarkers for detection of fungal infections

Fungal infection in the immunocompromised patient. Dr Kirsty Dodgson

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

Use of Antifungal Drugs in the Year 2006"

Invasive Aspergillosis in India: Unique Challenges. Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai

Atul Humar, MD, MSc Director, Transplant Program, University Health Network, University of Toronto

Micafungin, a new Echinocandin: Pediatric Development

Controversies in management: prophylaxis or diagnostics

Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.

Fungal Infection in the ICU: Current Controversies

Antifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul

New Directions in Invasive Fungal Disease: Therapeutic Considerations

Diagnostic Procedures for Pulmonary Infiltrates in the Compromised Host

Neutropenic Fever. CID 2011; 52 (4):e56-e93

ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST

Update on Antifungal Stewardship

MICROBIOLOGICAL TESTING IN PICU

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Title: Author: Speciality / Division: Directorate:

Primary prophylaxis of invasive fungal infection in patients with haematological diseases

Therapy of Hematologic Malignancies Period at high risk of IFI

Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients

High risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR

Cigna Drug and Biologic Coverage Policy

Fungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA

Introduction. Study of fungi called mycology.

Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies

Complications after HSCT. ICU Fellowship Training Radboudumc

Objec&ves. Clinical Presenta&on

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing

Risks and outcome of fungal infection in neutropenic children with hematologic diseases

How to make a fast diagnosis

Microbiological diagnosis of infective endocarditis; what is new?

Research priorities in medical mycology

ADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia

ESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole

Aspergillosis in Pediatric Patients

Abstract. Introduction

number Done by Corrected by Doctor د.حامد الزعبي

Antifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?

FEBRILE NEUTROPENIA CURRENT GUIDELINES FOR CHILDREN Alia Zaidi, MD. St. Jude International Outreach Program

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?

CHEST (NTMG) (VATS) (MGFA) VATS. NTMG Kaplan-Meier (CSR) y CSR Kaplan-Meier. (minimally invasive surgery); (myasthenia gravis);

Scottish Medicines Consortium

Micafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia

Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.

HISTOPLASMOSIS - LABORATORY DIAGNOSIS IN VIETNAM

Hema e-chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections

Antifungal therapy guidelines

Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B

Voriconazole October 2015 Risk Management Plan. Voriconazole

Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital

anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd

Department of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2

Condition First line Alternative Comments Candidemia Nonneutropenic adults

Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston

Transcription:

Fungal Infections in Neutropenic Hematological Disorders 23

Dr Farah Jijina 24

Fungal Infections in Neutropenic Hematological Disorders 25

Dr Farah Jijina 26

Fungal Infections in Neutropenic Hematological Disorders 27

Dr Farah Jijina 28

Fungal Infections in Neutropenic Hematological Disorders 29

Dr Farah Jijina 30

Fungal Infections in Neutropenic Hematological Disorders 31

Dr Farah Jijina 32

Fungal Infections in Neutropenic Hematological Disorders 33

Dr Farah Jijina 34

Fungal Infections in Neutropenic Hematological Disorders 35

Dr Farah Jijina 36

Case 2 (contd..) Day + 25 (20/1/06) Afebrile except for fever spikes with Amphotericin B. Day + 29: Received 2300mg Amphotericin B. Unable to tolerate. Creatinine rising, hypokalemia Change to Voriconazole (Vfend) Day + 30: Neutrophil recovery (700/cu mm). Day + 37 (06 Feb 2006) On oral Voriconazole Rpt BM: In Remission Discharge on Voriconazole, Augmentin, Levofloxacin 37

10 Mar 2006: After 1 Consolidation 03 April 2006: After 2 Consolidation 38

Question 5: The following is a criteria for PROVEN Fungal Infection Candida cultured from catheterised Urine Galactomannan test in Plasma for Zygomycosis Tissue biopsy showing fungal hyphae with accompanying tissue damage 1-3 beta-d-glucan test in serum for Aspergillosis Question to Col J Kotwal How do we diagnose Systemic Fungal Infections in ICU settings or Immunocompromised Hosts? (Excluding Endemic Fungal Infections) 39

Associate Professor in Pathology and Senior Adviser in Pathology and Hematology Armed Forces Medical College, Pune Formerly at Army Hospital Research & Referral, New Delhi Graduate of Lady Hardinge Medical College, New Delhi. Post Graduate, AFMC, Pune. Post-Doctoral Fellowship in Hematopathology at All India Institute of Medical Sciences, New Delhi Gold Medal for Standing First in MD (Pathology examination), Pune University Col Jyoti Kotwal MBBS, MD (Pathology) Abstract Histological and cultural evidence from tissue biopsies or resected material is required for definitive diagnosis of systemic fungal infections. However it is not always possible to fulfil this criterion. The current methods of diagnosis of IFI include signs and symptoms, microscopy, culture, serology, imaging procedures and biopsy. All tissues from patients with suspected systemic fungal infections should be stained with special fungal stains (GMS and PAS) as grams stain and H&E stain may miss out the fungal infection or misinterpret it as fibrin filaments. As far as culture is concerned, reliable results can be obtained from normally sterile body fluids like blood, CSF, pleural effusion and biopsy material. These fungi should then be identified till the species level. Despite stringent repeated cultures only 50% of autopsy proven candidiasis have positive blood culture. Thus thre is an important role of serology. Several antigen and antibody test methods have been used for systemic fungal infections. Antibody tests have a sensitivity of 17-90%, but the tests show delayed or decreased reaction in immuno-supressed and thus have a limited role. The antigen detection tests like CandTec have more utility. The antibody test has no role in diagnosis of aspergillosis. However the FDA approved galactomannan antigen assay shows high sensitivity and specificity, especially now with the lowered cut-offs for the test. However there is a problem of false negative in paediatric patients and those on anti-mycotic therapies and of false positivity in patients on â-lactam antibiotics. The use of this test is in the nascent stage in India and has been tried at CMC, Vellore and SGRH, New Delhi. There may be a major role for PCR for the early detection of systemic fungal infections and in this context the use of rapid multiplex PCR techniques which take 6 hrs to give results need to be clinically evaluated. This is still used as a research toll and is not available for clinical use. For mucor mycosis, tissue diagnosis is the major diagnostic method as no reliable serological, PCR based or skin tests are available. Pan fungal PCR on serial serum samples might be useful for diagnosis of disseminated mucor mycosis and is under evaluation. To conclude, a combination of various methods with regular screening are necessary for early diagnosis of systemic fungal infections. 40

Laboratory Diagnosis of Systemic Fungal Infections 41

Col Jyoti Kotwal 42

Laboratory Diagnosis of Systemic Fungal Infections 43

Col Jyoti Kotwal 44

Laboratory Diagnosis of Systemic Fungal Infections 45

Col Jyoti Kotwal 46

Laboratory Diagnosis of Systemic Fungal Infections 47

Col Jyoti Kotwal 48

Question 6: If Resources are not a constraint, the Drug of Choice for Invasive Aspergillus is Itraconazole Amphotericin D Caspofungin Voriconazole Question to Dr Eric Bow What are the Guidelines for Systemic Fungal Infections and New Anti-Fungal Agents 49

Dr. Eric J. Bow MD, MSc, D. Bacteriol, FRCPC Professor and Head, Section of Haematology/Oncology Department of Internal Medicine, University of Manitoba. Head, Department of Medical Oncology and Haematology, and Director, Infection Control Services, CancerCare Manitoba, Canada. Professor of Medicine and Medical Microbiology at the University of Manitoba, Winnipeg. Graduated from the University of Calgary Trained in General Internal Medicine and Haematology at McMaster University, Clinical Microbiology at the University of Toronto, and in Infectious Diseases at the University of Manitoba. Member of the Manitoba Blood and Marrow Transplant (MBMT) Program. Research interests: o Prevention and management of bacterial and fungal infections in neutropaenic cancer patients o Cytotoxic therapy-induced intestinal epithelial damage o Management strategies in adult acute myeloid leukemia o Impact of cytotoxic therapy on quality of life in cancer patients. 50

Guidelines to Manage Systemic Fungal Infections 51

Dr. Eric J. Bow 52

Guidelines to Manage Systemic Fungal Infections 53

Dr. Eric J. Bow 54

Guidelines to Manage Systemic Fungal Infections 55

Dr. Eric J. Bow 56

FEEDBACK FROM THE DELEGATES SYMPOSIUM ON SYSTEMIC FUNGAL INFECTIONS In order to improve future meetings, your feedback is important. Please fill this form and hand it over to the faculty or Volunteers. Please give your opinion on a scale of 1-4 (1=poor, 2=average, 3=good, 4=excellent) regarding the following aspects. 1. How would you rate this Symposium as a CME program. [ ] 2. How relevant was the topic [ ] 3. Rate the Audiovisual presentation [ ] 4. Rate the Booklet [ ] 5. Rate the Faculty [ ] Special comments. 6. Was the interaction time adequate [ ] 7. Would you recommend Case Based Discussions in future conferences. 8. Suggest Future topics Thank You for Your Time!

Question Addressed to: Name of Faculty..... Question:.................. Name and Institution of Delegate (Optional)..... Question Addressed to: Name of Faculty... Question:.................. Name and Institution of Delegate (Optional).....